Granulocyte/monocyte apheresis as immunotherapic tool: Cellular adsorption and immune modulation

Autoimmunity Reviews

Volumn 8, Issue 4, 2009, Pages 292-296

  Cuadrado, Emilio ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

Granulocyte monocyte apheresis; Inflammatory bowel disease; Regulatory T cells

Indexed keywords

CHEMOKINE RECEPTOR; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTAGONIST; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 35; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P40; NATALIZUMAB; STEROID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADSORPTION; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CANCER RISK; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTERITIS; GRANULOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LEUKAPHERESIS; MICROSCOPIC MICROANGIITIS; MONOCYTE; NEOPLASM; NONHUMAN; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADSORPTION; GRANULOCYTES; HUMANS; IMMUNE SYSTEM PROCESSES; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; MONOCYTES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 61349120146     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.09.001     Document Type: Review

References (40)

1. Saniabadi A.R., Hannai H., Takeuchi K., Umemura K., Nakashima M., Adachi T., et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Therap Apher Dial 7 (2003) 48-59
2. Hiraishi K., Takeda Y., Shiobara N., Shibusawa H., Gima F., Kashiwagi N., et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte apheresis. Therap Apher Dial 7 (2003) 334-340
3. Aoki H., Nakamura K., Yoshimatsu T., Tsuda Y., Irie M., Fukuda K., et al. Adacolumn selective leukocyte adsorption apheresis in patients with ulcerative colitis: clinical efficacy, efects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 52 (2007) 1427-1433
4. Andoh A., Tsujikawa T., Inatomi O., Deguchi Y., Hata K., Kitoh K., et al. Suppression of inflammatory cytokine secretion by granulocyte/monocyte adsorptive apheresis in active ulcerative colitis. Therap Apher Dial 9 (2005) 123-127
5. Yagi Y., Andoh A., Ogawa A., Bamba S., Tsujikawa T., Sasaki M., et al. Microarrays analysis of leukocytapheresis-induced changes in gene expression patterns of peripheral blood mononuclear cells in patients with ulcerative colitis. Therap Apher Dial 11 (2007) 331-336
6. hig+CD4+ and high pro-inflammatory CD28-CD4+ T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 52 (2007) 2725-2731
7. Sather B.D., Treuting P., Perdue N., Miazgowick M., Fontenot D., Rudensky A.Y., et al. Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 204 (2007) 1335-1347
8. Rembacken B.J., Newbould H.E., Richards S.J., Misbah S.A., Dixon M.E., Chalmers D.M., et al. Granulocyte apheresis in inflammatory bowel disease possible mechanisms of effect. Therap Apher 2 (1998) 93-96
9. Kristensen N.N., Gad M., Thomsen A.R., Lu B., Gerard C., and Claesson M.H. CXC chemokine receptor 3 expression increases the disease-inducing potential of CD4+CD25- T cells in adoptive transfer colitis. Inflamm Bowel Dis 12 (2006) 374-381
10. Schneider M.A., Meingassner J.G., Lipp M., Moore H., and Rot A. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory cells. J Exp Med 204 (2007) 735-745
11. Davalos-Misslitz A.C., Rieckenberg J., Willenzon S., Worbs T., Kremer E., Bernardt G., et al. Generalized multiorgan autoimmunity in CCR7-deficient mice. Eur J Immunol 37 (2007) 613-622
12. Becker C., Wirtz S., Blessing M., Worbs T., Kremer E., Bernardt G., et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112 (2003) 693-706
13. Rudensky A.Y., and Campbell D.J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 203 (2006) 489-492
14. Denning T.L., Wang Y.C., Patel S.R., Williams I.R., and Pulendran B. Lamina propia macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 8 (2007) 1086-1094
15. Kühn R., Rennick D., Rajewsky K., and Müller W. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
16. Marie J.C., Letterio J.J., Gavin M., and Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+ CD25+ regulatory T cells. J Exp Med 201 (2005) 1061-1067
17. Acosta-Rodriguez E.V., Napolitano G., Lanzavecchia A., and Sallusto F. Interleukins 1-beta and 6 but not TGF beta are essential for the differentiation of IL-17-producing human T helper cells. Nature Immunol 8 (2007) 903-905
18. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17 T helper cells. Cell 126 (2006) 1121-1133
19. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., Mckenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
20. Rennick D.M., Fort M.M., and Davidson N.J. Crossing mice double deficient for IL-10 with IL-12 develop comparable colitis, whereas mice double deficient for IL-10 and IL-23 fail to develop intestinal bowel disease. J Leukoc Biol 61 (2006) 389-396
21. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., et al. Both IL-12 p70 and IL23 are synthesized during active Crohn's disease and are down regulated by treatment with anti IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12 (2006) 9-15
22. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panapoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448 (2007) 480-483
23. Fujino S, Andoh A, Bamba S, Ogawa A, Ata K, Araki Y. 2004., Increased expression of IL-17 in inflammatory bowel disease. Gut 2003, 52, 65-70.
24. Ogawa A., Andoh A., Araki Y., Bamba T., Fujiyama Y., et al. Neutralization of IL-17 aggravates dextran sulphate sodium-induced colitis in mice. Clin Immunol. 110 (2004) 55-62
25. Andoh A., Zhang Z., Inatomi O., Fujino S., Deguchi Y., Araki Y., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129 (2005) 969-984
26. Niedabala W., Xei X.Q., Cai B., Hueber A.J., Leung B.P., McInnnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells (2007) 3021-3029
27. Jankovic D., Trinchieri G., Jankovic D., and Trinchieri G. IL-10 or not IL-10; that is the question. Nat. Immunol 8 (2007) 1281-1283
28. Schmidt C., Giese T., Ludwig B., Mueller-Molaian I., Marth T., Zeuzem S., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated IL-23p19 and IL-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 16-23
29. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trial. JAMA 295 (2006) 2275-2285
30. Atzeni F., Ardizzone S., Sarzi-Puttuni P., Colombo E., Maconi G., DePortu S., et al. Autoantibody profile during short-time infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther 22 (2005) 453-461
31. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-IL12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
32. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132 (2007) 1672-1683
33. Jonson F.R., Ozdemir S., Mansfield C., Hass S., Miller D.W., Siegel C.A., et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133 (2007) 769-779
34. Sherer Y., and Shoenfeld Y. Intravenous immunoglobulin for modulation of systemic lupus erythematosus. Autoimmun Rev 5 (2006) 153-155
35. Vani J., Elluru S., Negi V.S., et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 7 (2008) 440-444
36. Hanai H., Lacrois-Desmazes S., Kazatchkine M.D., Bayary J., et al. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 12 (2006) 7568-7577
37. Suzuki Y., Yoshimura N., Saniabadi A., and Saito Y. Selective granulocyte/monocyte apheresis therapy as a first-line treatment for steroid naïve patients with active ulcerative colitis; a prospective uncontrolled pilot study. Dig Dis Sci 49 (2004) 565-571
38. Bresci G., Parisi G., Mazzoni A., Scatena F., and Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy versus granulocytapheresis. Dig Liver Dis 39 (2007) 430-437
39. Kanekura T., Kawahara K., Maruyama I., and Kanzaki T. Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. Therap Apher Dial 9 (2005) 292-296
40. Cuadrado E., Alonso M., De Juan M.D., Echaniz P., and Arenas J.I. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J Gastroenterol 14 (2008) 1521-1527